Peer-influenced content. Sources you trust. No registration required. This is HCN.

Monthly Prescribing Reference (MPR)FDA Approves First-in-Class Treatment for Type 2 Diabetes

Mounjaro (tirzepatide) is a first-in-class, once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule. It enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. The FDA approval of Mounjaro as an adjunct therapy to diet and exercise for adults with type 2 diabetes was based on clinical trials where treatment with Mounjaro resulted in statistically significant reduction in both A1c and weight vs. semaglutide, insulin degludec, and insulin glargine.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form